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A large fraction of genetic risk factors for Alzheimer’s Disease (AD) is still not identified, limiting 
the understanding of AD pathology and study of therapeutic targets. We conducted a genome-
wide association study (GWAS) of AD cases and controls of European descent from the multi-center 
DemGene network across Norway and two independent European cohorts. In a two-stage process, 
we first performed a meta-analysis using GWAS results from 2,893 AD cases and 6,858 cognitively 
normal controls from Norway and 25,580 cases and 48,466 controls from the International Genomics 
of Alzheimer’s Project (IGAP), denoted the discovery sample. Second, we selected the top hits 
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(p < 1 × 10−6) from the discovery analysis for replication in an Icelandic cohort consisting of 5,341 cases 
and 110,008 controls. We identified a novel genomic region with genome-wide significant association 
with AD on chromosome 4 (combined analysis OR = 1.07, p = 2.48 x 10−8). This finding implicated 
HS3ST1, a gene expressed throughout the brain particularly in the cerebellar cortex. In addition, we 
identified IGHV1-68 in the discovery sample, previously not associated with AD. We also associated 
USP6NL/ECHDC3 and BZRAP1-AS1 to AD, confirming findings from a follow-up transethnic study. These 
new gene loci provide further evidence for AD as a polygenic disorder, and suggest new mechanistic 
pathways that warrant further investigation.
Alzheimer’s disease (AD), the most common cause of dementia1,2, places a large personal and economic burden 
on families and society3,4. There are nearly 200,000 individuals suffering from AD in the Nordic countries alone 
(http://www.alzheimer-europe.org). In the absence of disease-modifying therapies, identifying AD prevention 
strategies is of importance. Converging evidence indicates that AD-associated pathological changes5 begin years, 
if not decades, before the onset of clinical symptoms6–8. In order for targeted prevention to be most effective, there 
is a need to better identify the genetic AD architecture to determine pre-symptomatic disease risk, as well as to 
provide new insight into disease mechanisms.
Multiple genes in combination with environmental risk factors affect AD neurodegeneration9,10. Apart from 
the major genetic risk factor of the APOE gene11–13, late onset AD does not exhibit a clear-cut pattern of inher-
itance and is probably caused by many common variants, each with a small effect9,14–19 (‘polygenic’), together with 
few rare variants with large effects9,19–22. In a genome-wide association study (GWAS), SNPs tagging these causal 
variants may be identified as association loci. In a large, two-stage GWAS meta-analysis15, 19 loci were associated 
with AD in addition to the previously reported APOE locus. Yet these sequence variants account only for a small 
portion of the disease heritability23–26. This “missing heritability” has been attributed to a number of potential 
causes, such as lack of typing of rare variants26, and lack of proper statistical methods for analyzing the polygenic 
architecture of AD. A concerted effort to increase sample sizes is required to reveal the small-effect genetic risk 
variants which are common in the population.
We conducted a GWAS of 2,893 AD cases and 6,858 controls from a Norwegian cohort and meta-analyzed 
this cohort with the publicly available IGAP GWAS data15. The most promising association signals were tested 
in an independent replication sample from Iceland. A novel locus was uncovered on chromosome 4 (rs6448807; 
hg19 chr4:11676144, OR = 1.07, p = 2.48 × 10−8). This novel locus is close to the HS3ST1 gene, suggesting the 
involvement of a new biochemical pathway in AD pathology.
Methods
Samples. Norwegian cohorts. We collected genotype data from the Norwegian DemGene network con-
sisting of 2,893 cases and 1,660 healthy controls. A total of 4,553 Caucasian (1000 Genome population code: 
CEU) individuals were recruited and successfully genotyped. DemGene is a Norwegian network of clinical sites 
collecting cases from Memory Clinics based on standardized examination of cognitive, functional and behavioral 
measures and data on progression of most patients. We diagnosed 2,135 cases of AD dementia as well as 758 cases 
of Mild Cognitive Impairment (MCI) as a proxy of prodromal AD, from 7 studies (mean age = 73.2 ± 9.9): the 
Norwegian Register of persons with Cognitive Symptoms (NorCog), the Progression of Alzheimer’s Disease and 
Resource use (PADR), the Dementia Study of Western Norway (DemVest), the AHUS study, the Dementia Study 
in Rural Northern Norway (NordNorge), HUNT Dementia Study and the Nursing Home study, the TrønderBrain 
study, and the Dementia Disease Initiation study (DDI). Cases were diagnosed with dementia due to Alzheimer’s 
disease according to the recommendations from the National Institute on Aging–Alzheimer’s Association (NIA/
AA) (AHUS), the NINCDS-ADRDA criteria (DemVest and TrønderBrain) or the ICD-10 research criteria 
(NorCog, PADR, NordNorge and HUNT). MCI was diagnosed according to the NIA-AA criteria (AHUS and 
DDI) or the Winblad criteria (NorCog, HUNT, PADR, DemVest, Trønderbrain). The controls from Norway were 
obtained through AHUS, NordNorge, HUNT and TrønderBrain studies. Controls were screened with standard-
ized interview and cognitive tests from the population. To increase the statistical power of our association analy-
sis, the controls were combined with additional 4,475 population controls from Norwegian blood donor samples 
(Oslo University Hospital, Ullevål Hospital, between 18–60 years) and 723 controls from the Thematically 
Organized Psychosis Research (TOP) Study27 (between 25–65 years). Control subjects from the TOP Study were 
of Caucasian origin without history of moderate/severe head injury, neurological disorder, mental retardation 
and were excluded if they or any of their close relatives had a lifetime history of a severe psychiatric disorder, a 
history of medical problems thought to interfere with brain function or significant illicit drug use27. The inclusion 
of population controls were corrected for population stratification28. For a complete description of the samples, 
please refer to Supplementary Text 1 and Supplementary Table 1.
Genotyping. The genotypes for the DemGene Study were obtained with Human Omni Express-24 v.1.1 
(Illumina Inc., San Diego, CA, USA) at deCODE Genetics (Reykjavik, Iceland).
IGAP Study. We obtained summary statistic GWAS data from the IGAP Study, a large two-stage meta-analysis 
of GWAS in individuals of European ancestry. In stage 1, genotyped data were imputed into 7,055,881 SNPs to 
perform meta-analysis on 4 previously published GWAS data sets from four consortia: the Alzheimer’s Disease 
Genetic Consortium (ADGC), the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
Consortium, the European Alzheimer’s Disease Initiative (EADI) and the Genetic and Environmental Risk in 
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Alzheimer’s Disease (GERAD) Consortium, consisting of 17,008 AD cases and 37,154 controls. In stage 2, 11,632 
SNPs were genotyped and tested for association in an independent set of 8,572 AD cases and 11,312 controls.
Sample from Iceland. Patients from Iceland were diagnosed with definite, probable or possible AD dementia 
on the basis of the NINCDS-ADRDA criteria or according to guidelines for ICD-10 F00 and were compared to 
population controls17. Association testing was carried out using information from 5,341 AD patients and 110,008 
population controls, adjusting for age, age-squared, sex and county of birth.
The case-control studies are summarized in Table 1.
Analysis. Before imputation, the genotype data underwent basic quality control including removal of SNPs 
with minor allele frequency (MAF) lower than 0.01, genotype call rate lower than 0.95, less than one in a million 
probability of being in Hardy-Weinberg equilibrium (for both cases and controls) and ambiguous strand assign-
ment (A/T, C/G SNPs). The quality-controlled genotypes were used to compute genetic principal components 
analysis (PCA) with which to adjust for potential population stratification effects. PCA was performed using 
PLINK 1.9 based on the variance-standardized relationship matrix29.
MaCH software30 was used to impute the genotypes of all participants onto reference haplotypes derived from 
samples of European ancestry in the 1000 Genome Project (Build 37, Assembly Hg19)31. SNPs with MAF lower 
than 0.005 or a ratio of observed versus expected variance lower than 0.1 were excluded. The association of LOAD 
with genotype dosage was analyzed in PLINK 1.9 with a logistic regression model using gender and 20 top prin-
cipal components as covariates. Sex chromosomes were not included from the analyses29. After filtering for SNPs 
with information value greater than 0.5, we obtained 9,155,276 association p-values. The inflation factor of the 
DemGene sample was calculated at 1.022 (Supplementary Fig. 1).
We analyzed 6,564,314 SNPs that overlap between DemGene and IGAP stage 1 data and 10,092 SNPs with 
IGAP stage 2. A meta-analysis with IGAP data was performed using PLINK 1.9 with fixed effects inverse-variance 
weighted effect sizes29.
Functional Annotation (FUMA). We utilized FUMA for post-processing of our Stage 1 results32. FUMA 
incorporates 18 biological data repositories such as the Genotype-Tissue Expression (GTEx), Encyclopedia of 
DNA Elements (ENCODE), Roadmap Epigenomics Project and chromatin interaction information. FUMA 
requires GWAS summary statistics and outputs multiple tables and figures containing extensive information on, 
e.g., functionality of SNPs in genomic risk loci, including protein-altering consequences, gene-expression influ-
ences, open-chromatin states as well as three-dimensional (3D) chromatin interactions. Functionally annotated 
SNPs are subsequently mapped to prioritized genes based on (i) physical position mapping on the genome, (ii) 
expression quantitative trait loci (eQTL) mapping and (iii) 3D chromatin interactions (chromatin interaction 
mapping)32. Biological information for each prioritized gene is provided to gain insight into previously associated 
diseases. Beside the single gene level analyses, FUMA uses GTEx to identify 53 tissue specific expression levels 
of prioritized genes. We refer to the original publication for details on the methods and repositories of FUMA32.
Results
We performed GWAS in two stages33,34. First, we meta-analyzed the discovery samples using 10,092 SNPs 
imputed for both the DemGene and IGAP stage 1 + 2 samples (Manhattan plots in Fig. 1). From this discov-
ery sample result, we narrowed our analysis to 1,035 SNPs with genome-wide or suggestive association (meta 
p < 1 × 10−6) and tested these SNPs in an Icelandic replication sample. Finally, we meta-analysed the discovery 
and replication samples into a combined analysis.
We identified 20 genomic risk loci from the discovery sample using FUMA (r2 > 0.1 using Linkage 
Disequilibrium from 1000 Genomes hg1931), listed in Supplementary Table 2. Four out of the 20 loci had not 
reached genome-wide significance in IGAP at p < 5 × 10−8. We list the lead SNPs of the discovery sample in 
Table 2 and the corresponding lead SNPs of the combined analysis in Supplementary Table 3.
We highlight a genomic region on chromosome 4 spanning 11.55 Mb–11.76 Mb (best SNP: rs6448807, dis-
covery OR = 1.08, p = 2.23 × 10−8) in Fig. 2. The lead SNP is located at position chr4:11676144 (minor/major 
allele: C/T), an intron of gene RP11-281P23.2, a non-coding RNA (Ensembl: ENSG00000249631). Its nearest 
protein-coding gene is HS3ST1 located 240 kb away. We found the same direction of effects within the replica-
tion sample (replication OR = 1.03, p = 0.17), and in the combined analysis the SNP is associated with AD at 
p = 2.48 × 10−8 (Table 2). Although this lead SNP of the discovery sample was not replicated at p < 0.05 in the 
replication sample, we found rs13133131 within the same genomic locus as a proxy SNP (r2 = 0.94) with better 
Cases (MCI) Percent Women Age Controls
DemGene* 2,893 (758) 60 73.2 ± 9.9 6,858
IGAP
  -Stage 1 17,008 61.3 74.2 37,154
  -Stage 2 8,572 64.7 74.4 11,312
Discovery 28,473 55,324
Replication 5,341 110,008
Table 1. Samples. *Cases include Alzheimer’s Disease (AD) dementia and Mild Cognitive Impairment (MCI). 
IGAP and replication cases include AD dementia only.
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replication (replication p = 0.00319) and a stronger association in the combined analysis (combined OR = 1.07, 
p = 8.16 × 10−9), see Supplementary Table 3 for genomic risk loci based on the combined analysis.
Additionally we found a genomic region on chromosome 14 spanning 106.47 Mb–107.26 Mb with a novel 
risk associated locus at rs79452530 (chr14:107156009, OR = 0.89, p = 2.36 × 10−8), see Fig. 2. This is an inter-
genic SNP 3,860 kb away from the nearest gene IGHV1-68 (Ensembl: ENSG0000253703). The locus has not 
previously been associated with AD, but was mentioned in a study in rheumatic heart disease35. This genomic 
region was genome-wide significant in the discovery sample, but its effect was not observed in the replication 
sample (Table 2) and none of its proxies passed the significance threshold in the combined analysis (best SNP: 
rs78631692 at p = 6.57 × 10−8, Supplementary Table 3). The directions of effects, however, were consistent in all 
samples (Table 2).
We also found association regions at genome-wide significance at two additional loci on Chromosome 
10 and 17, both of which had not passed significance threshold in the IGAP study. The first locus, rs7920721 
(chr10:11720308, OR = 1.07, p = 1.82 × 10−8), is an intergenic SNP with nearest gene RP11-138I18.2 (Ensembl: 
ENSG00000271046) at 1366 kb away and in between protein-coding genes USP6NL/ECHDC3 (see Supplementary 
Fig. 2). This SNP is replicated at p = 0.0072 and has a strong association signal in the combined analysis 
(OR = 1.07, p = 4.84 × 10−10). The second locus, SNP rs2526378 (chr17:56404349, OR = 0.93, p = 3.64 × 10−9), 
is an intron of non-coding RNA BZRAP1-AS1 (Ensembl: ENSG00000265148) (Supplementary Fig. 2). A proxy 
of this SNP (r2 = 0.96) is significant in the combined analysis at p = 3.58 × 10−8, although it is mainly driven by 
the discovery sample (Supplementary Table 3). For both rs7920721 and rs2526378, we found agreement of its 
significance in a following transethnic AD study36, confirming our results.
We focused our FUMA analyses on the two novel loci in our study, the two genomic regions on chromosomes 
4 and 14, represented by lead SNPs rs6448807 and rs79452530. Out of the functional consequences of 1,128 SNPs 
represented by the two loci on genes, we found the most SNPs being intergenic (n = 511 SNPs) and non-coding 
RNA-intronic (n = 340), see Supplementary Fig. 3. For the chromosome 4 locus, we mapped the associated vari-
ants through eQTL or 3-D chromatin interaction to 15 genes, eight of which are protein-coding: BOD1L1, CLNK, 
HS3ST1, NKX3-2, RAB28, SLC2A9, WDR1 and ZNF518B (Fig. 3). Notably, HS3ST1 was mapping using both 
eQTL and chromatin interaction. For the chromosome 14 locus, we mapped the associated variants to 117 genes 
(Supplementary Figs 3 and 4). Despite the large number of genes located in the 780 kb-span of the genomic risk 
region, none of them was identified as a protein-coding gene by FUMA.
Furthermore, we looked at the expression and enrichment tests of the protein-coding genes prioritized by 
FUMA. We found WDR1 to be highly expressed in comparison to other genes in all tissues except brain tissue, 
where it is only moderately highly expressed (Supplementary Fig. 5). We also found higher expression in RAB28 
and BOD1L1 in all tissues. Although HS3ST1 is not highly expressed compared to other genes, its expression is 
specifically higher in the cerebellar hemisphere and the cerebellum. Lastly, we found IGHV-genes to have higher 
expression in the spleen, stomach, intestine and lung tissues, and lower expression specific to brain tissues.
Discussion
Our study presents the largest GWAS of AD cases and controls from multi-center network across Norway to date 
and its meta-analysis with two independent European cohorts. Our main finding in the present study is a novel 
locus associated with AD on chromosome 4, represented by rs6448807. Its closest protein-coding gene, HS3ST1, 
has been previously suggested as an AD susceptibility locus using conditional False Discovery Rate methods asso-
ciating AD with dyslipidaemia37, and here we discover the same locus using standard GWAS analysis. According 
to brain expression data from the BrainSpan Atlas of the Developing Human Brain38,39, HS3ST1 (Heparan sulfate 
D-glucosaminyl 3-O-sulfotransferase 1) is expressed in the brain, with strong expressions in the cerebellar cor-
tex, followed by the primary visual cortex. Similar heparan sulphate enzymes (HST3ST1, HS3ST2, HST3ST3A, 
HS3ST3B, HS3ST4 and HS3ST5) are expressed in human elderly hippocampus40, with HS3ST2 already proven to 
be overexpressed in the hippocampus of patients with AD41. Similarly, heparan sulfates have been shown in mice 
Figure 1. Manhattan plots of discovery sample from meta-analysis of DemGene data with IGAP 1 + 2. Note 
that color alternate between chromosomes for visualization only. Out of the loci passing genome-wide threshold 
p < 5 × 10−8, we found novel hits on Chromosomes 4, 10, 14 and 17.
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CHR BP SNP A1/A2 MAF Gene
Discovery Replication Combined
Dir.OR p-value OR p-value OR p-value
4 11676144 rs6448807 T/C 0.30 RP11-281P23.2(HS3ST1) 1.08 2.23E-08 1.03 1.72E-01 1.07 2.48E-08 +++
10 11720308 rs7920721 G/A 0.27 RP11-138I18.2(USP6NL/ECHDC3) 1.07 1.82E-08 1.06 7.23E-03 1.07 4.84E-10 +++
14 107156009 rs79452530 T/C 0.16 IGHV1-68(IGHV1-68) 0.89 2.36E-08 0.97 3.08E-01 0.91 1.27E-07 —
17 56404349 rs2526378 G/A 0.47 BZRAP1-AS1(BZRAP1) 0.93 3.64E-09 0.99 6.69E-01 0.94 5.30E-08 —
Table 2. Genomic risk loci from the discovery sample which are not genome-wide significant in IGAP. CHR: 
chromosome; BP: base pair location; A1/A2: major/minor alleles; MAF: minor allele frequency in 1000 G. 
Gene: nearest gene and nearest protein-coding gene (in parentheses). OR: odds ratio; Dir.: direction of effects in 
the two discovery samples (Demgene, IGAP) and the replication sample (Iceland).
Figure 2. Regional association plots of rs6448807 (chr 4) and rs79452530 (chr 14) in the discovery sample. 
Mapping of the genes is strictly based on position of the genomic risk loci.
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to modulate brain amyloid-β clearance and aggregation in AD42. This study pointed to the implication of heparan 
sulphates to AD.
In a previous large AD study by IGAP15, a proxy to this SNP (r2 = 0.79) had been listed as a suggestive asso-
ciation locus (rs6448799; hg19 chr4:11630049). The gene HS3ST1 is located 197 kb from rs6448799 and 245 kb 
from rs6448807. This finding adds another risk variant with a low odds ratio to the polygenic risk factors of AD. 
rs6448807 and rs644879915 are located in the first intron of non-coding RNA RP11-281P23. The Ensembl gene 
model for RP11-281P23 is supported by expressed sequence tag evidence from testes and kidney, and RNA-seq 
data provide evidence of expression in the heart, testes43 and brain (dorsolateral prefrontal cortex)44 although 
expression levels are low in all these tissues. Based on the available data, it is not possible to conclude on which 
molecule is driving the association. The genetic evidence would tend to suggest that it is the non-coding RNA that 
underlies the association given that 1) both the genome-wide significant rs6448807 and the suggestive association 
locus rs6448799 are located near the transcription start site of the long non-coding RNA, 2) HS3ST1 is 245 kb 
away from these loci, and 3) there is little linkage disequilibrium between the HS3ST1 and the RP11-281P23 
locus. On the other hand, FUMA analyses point to the priority of HS3ST1 through not only eQTLs but also 
chromatin interactions. HS3ST1 has low but consistent expression in the cerebellar and visual cortex38,39 as well 
as the differential expression in brain between AD cases and controls37 provide supportive evidence for HS3ST1 
playing an important role. Further experimental research will be required to elucidate the biological basis of the 
association of this locus with AD.
Furthermore, we have boosted three genomic loci from the previous IGAP study into genome-wide signif-
icance. Two of the three loci are confirmed in a following study in transethnic meta-analysis study and here we 
observed them in a CEU population. The two loci are an intron on a non-coding RNA BZRAP1-AS1 and an 
intergenic SNPs with closest gene RP11-138I18.2.
From the discovery sample, we associated IGHV1-68 to AD, previously not associated with the disease. 
IGHV1-68 is a pseudogene within the immunoglobulin heavy chain (IGH) locus45. Although the exact role of 
IGHV1-68 is unknown, IGH is essential for biosynthesis of antibodies, a key component of the adaptive immune 
Figure 3. Circos plots of mapped gene on chromosome 4 locus. Genomic risk loci are highlighted in blue. 
Genes are mapped by 3-D chromatin interaction (orange) or eQTLs (green), or both (red) notably gene 
HS3ST1.
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response46. Interestingly, a recent GWAS-study associated IGHV1-68 with the aberrant immune response asso-
ciated with rheumatic heart disease35. However, the association with AD is novel, and warrants further studies 
into immunological pathways in AD47. A potential weakness of the present study entails the inclusion of younger 
population controls and the inclusion of MCI cases diagnosed with the Winblad criteria which lack AD bio-
marker profiling. While the population controls boosted the statistical power in our study, it may include controls 
that may later develop AD at disease prevalence rate. Thus, this study might not have reached its potential full 
statistical power. On the inclusion of MCI cases, although not all subjects diagnosed with MCI will ultimately 
develop AD, a large proportion of those with amnestic MCI and mixed type of MCI are expected to develop AD48. 
The potential inclusion of non-AD MCI cases may have reduced the strength of our findings. However, this only 
reduces the chance of finding GWAS loci, i.e. likely induce type-II errors but does not affect the rate of type-I 
errors.
To conclude, our findings further demonstrate the polygenic architecture of AD, and unveil potential mecha-
nisms including the immune system involved in AD pathobiology that warrant further investigation.
Data Availability
Genotype datasets from the Norwegian DemGene network generated and analysed during the current study 
are not publicly available due to compliance to privacy. Summary statistics are available from the corresponding 
author on reasonable request. The summary statistics from IGAP are publicly available at http://web.pasteur-lille.
fr/en/recherche/u744/igap/igap_download.php. Data from Icelandic study are available from deCODE Genetics 
on reasonable request.
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